US 10132810
Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor
granted A61KA61K31/4745A61K47/60
Quick answer
US patent 10132810 (Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor) held by Nektar Therapeutics expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Nektar Therapeutics
- Grant date
- Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K31/4745, A61K47/60